7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Uremia D014511 33 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Neoplasms, Experimental D009374 10 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Armstrong AP et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. 2008 Prostate pmid:18008334
Hesry V et al. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. 2006 Prostate pmid:16541419
Zheng Y et al. Vitamin D deficiency promotes prostate cancer growth in bone. 2011 Prostate pmid:21541977
Helo S et al. Role of denosumab in prostate cancer. 2012 Prostate Cancer Prostatic Dis. pmid:22370723
Quinn JE et al. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. 2005 Prostate Cancer Prostatic Dis. pmid:15999121
Vandyke K et al. Androgen decreases osteoprotegerin expression in prostate cancer cells. 2007 Prostate Cancer Prostatic Dis. pmid:17189957
Liu Z et al. Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. 2004 Protein Pept. Lett. pmid:15327363
Janda K et al. [The relationship between advancement of secondary hyperparathyroidism and selected calcification parameters in peritoneal dialysis patients]. 2012 Prz. Lek. pmid:23750431
Czyzewska-Buczyńska A et al. [Assessment of osteopontin and osteoprotegerin levels in abdominal aortic aneurysm patients]. 2013 Prz. Lek. pmid:24003660
Ziółkowska H and Roszkowska-Blaim M [Osteoprotegerin and calcium-phosphorus metabolism parameters in children with chronic renal failure]. 2006 Prz. Lek. pmid:16898492
Komosińska-Vassev K et al. [Osteoporosis--pathophysiology and laboratory diagnostic methods]. 2010 Prz. Lek. pmid:21387765
Kahl KG et al. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. 2006 Sep-Oct Psychosom Med pmid:17012519
Minenna G et al. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. 2005 Recenti Prog Med pmid:16229324
Heymann MF et al. OPG, RANK and RANK ligand expression in thyroid lesions. 2008 Regul. Pept. pmid:18367263
Kadoglou NP et al. Arterial stiffness and novel biomarkers in patients with abdominal aortic aneurysms. 2012 Regul. Pept. pmid:22982141
Crisafulli A et al. Osteoprotegerin and bone mineral density in hemodiafiltration patients. 2005 Ren Fail pmid:16152990
Pobeha P et al. Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD. 2014 Respir Med pmid:24424018
Bai P et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. 2011 Respir. Res. pmid:22176920
Bogliolo L et al. Biomarkers and prognostic stratification in psoriatic arthritis. 2012 Reumatismo pmid:22690385
Riancho JA and Delgado-Calle J [Osteoblast-osteoclast interaction mechanisms]. 2011 Reumatol Clin pmid:21924211
Sasso GR et al. Elevated serum osteoprotegerin levels in women: friend or foe? 2015 Nov-Dec Rev Assoc Med Bras (1992) pmid:26841162
Collantes Estévez E and González Domínguez J [Bone Paget's disease in the young adult]. 2004 Rev Clin Esp pmid:15456600
Ciacli C et al. [Bone turnover markers evaluation in psoriatic arthritis]. 2008 Jul-Sep Rev Med Chir Soc Med Nat Iasi pmid:20201244
Rosa-Rañal M et al. [New paradigms in the regulation of bone metabolism]. 2001 Jul-Aug Rev. Invest. Clin. pmid:11599485
Xu S et al. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. 2012 Rheumatol. Int. pmid:22057136
Skoumal M et al. The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis. 2008 Rheumatol. Int. pmid:18075741
Kanbe K et al. Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. 2012 Rheumatol. Int. pmid:21789615
Oelzner P et al. The balance between soluble receptors regulating IL-6 trans-signaling is predictive for the RANKL/osteoprotegerin ratio in postmenopausal women with rheumatoid arthritis. 2012 Rheumatol. Int. pmid:20821212
Rooney T et al. Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. 2010 Rheumatol. Int. pmid:19847430
Hein GE et al. sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. 2008 Rheumatol. Int. pmid:18172654
Stupphann D et al. Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. 2008 Rheumatol. Int. pmid:18369625
Yun HJ et al. Adrenomedullin inhibits MAPK pathway-dependent rheumatoid synovial fibroblast-mediated osteoclastogenesis by IL-1 and TNF-alpha. 2009 Rheumatol. Int. pmid:19116717
Agarwal S et al. Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. 2009 Rheumatol. Int. pmid:19052752
Zhou J et al. Pulsed electromagnetic field stimulates osteoprotegerin and reduces RANKL expression in ovariectomized rats. 2013 Rheumatol. Int. pmid:22948539
Keller KK et al. SKG arthritis as a model for evaluating therapies in rheumatoid arthritis with special focus on bone changes. 2013 Rheumatol. Int. pmid:22948540
Skoumal M et al. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. 2005 Rheumatol. Int. pmid:15889303
Yao Y et al. Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats. 2013 Rheumatol. Int. pmid:23334376
Pamuk BO et al. Evaluation of circulating endothelial biomarkers in familial Mediterranean fever. 2013 Rheumatol. Int. pmid:23358733
Chen J et al. OPG inhibits gene expression of RANK and CAII in mouse osteoclast-like cell. 2012 Rheumatol. Int. pmid:22210270
Kwon SR et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. 2012 Rheumatol. Int. pmid:21833531
Upton AR et al. The expression of RANKL and OPG in the various grades of osteoarthritic cartilage. 2012 Rheumatol. Int. pmid:21259010
Haynes DR et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. 2001 Rheumatology (Oxford) pmid:11426018
Corallini F et al. The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. 2009 Rheumatology (Oxford) pmid:19168833
Smith MD Comment on review on T cells in bone biology. 2004 Rheumatology (Oxford) pmid:15448222
Bezerra MC et al. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. 2005 Rheumatology (Oxford) pmid:16219645
Kwan Tat S et al. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. 2009 Rheumatology (Oxford) pmid:19762475
Huang CH et al. Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. 2011 Rheumatology (Oxford) pmid:20974615
Breland UM et al. Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. 2010 Rheumatology (Oxford) pmid:20231178
Haynes DR et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. 2003 Rheumatology (Oxford) pmid:12509625
Harashima SI et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. 2004 Rheumatology (Oxford) pmid:14963213

Table of Content